MEDIASEEK has been working on BrainTech, which fuses neuroscience and IT, for a long time. We are developing our business in the DTx (digital therapeutics) field with the cooperation with our business partners, utilizing the neurofeedback technology that we have developed to regulate the brain's condition.
We develop apps for treatment with a focus on illnesses of the central nervous system such as dementia, depression, and chronic pain (back pain) that are deemed to be particularly difficult to treat with drugs.

Also, MEDIASEEK, which is registered as a "medical device manufacturer", makes use of its past experience in developing apps to provide design and development services for apps for treatments for medical institutions that are superior in terms of usability as well.

Apps for treatments are officially known as medical device programs. Like existing medical devices, medical device programs refer to programs that aim to diagnose and treat diseases and are under the regulation of the Pharmaceutical and Medical Devices Act.
Thus, unlike normal apps, they have to meet the standards of medical devices as stipulated by the Minister of Health, Labor, and Welfare in terms of quality, effectiveness, ensuring safety, and so on. To carry out the development, it must be registered as a medical device manufacturer in every prefecture, and also, with regards to app development, in line with a standard called JIS T 2304 (IEC62304), there must be a classification of the safety class and development must be carried out while documenting the app development process, including risk management

At MEDIASEEK, we utilize BrainTech technology to research and develop therapeutic apps in the field of DTx.
As an open innovation-type joint business, for services' clinical trials, regulatory approvals, and sales, it partners with various research institutions, pharmaceutical companies, and so on.